Cargando…
Genomic features of rapid versus late relapse in triple negative breast cancer
BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct clinical and genomic features...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130400/ https://www.ncbi.nlm.nih.gov/pubmed/34006255 http://dx.doi.org/10.1186/s12885-021-08320-7 |
_version_ | 1783694518800875520 |
---|---|
author | Zhang, Yiqing Asad, Sarah Weber, Zachary Tallman, David Nock, William Wyse, Meghan Bey, Jerome F. Dean, Kristin L. Adams, Elizabeth J. Stockard, Sinclair Singh, Jasneet Winer, Eric P. Lin, Nancy U. Jiang, Yi-Zhou Ma, Ding Wang, Peng Shi, Leming Huang, Wei Shao, Zhi-Ming Cherian, Mathew Lustberg, Maryam B. Ramaswamy, Bhuvaneswari Sardesai, Sagar VanDeusen, Jeffrey Williams, Nicole Wesolowski, Robert Obeng-Gyasi, Samilia Sizemore, Gina M. Sizemore, Steven T. Verschraegen, Claire Stover, Daniel G. |
author_facet | Zhang, Yiqing Asad, Sarah Weber, Zachary Tallman, David Nock, William Wyse, Meghan Bey, Jerome F. Dean, Kristin L. Adams, Elizabeth J. Stockard, Sinclair Singh, Jasneet Winer, Eric P. Lin, Nancy U. Jiang, Yi-Zhou Ma, Ding Wang, Peng Shi, Leming Huang, Wei Shao, Zhi-Ming Cherian, Mathew Lustberg, Maryam B. Ramaswamy, Bhuvaneswari Sardesai, Sagar VanDeusen, Jeffrey Williams, Nicole Wesolowski, Robert Obeng-Gyasi, Samilia Sizemore, Gina M. Sizemore, Steven T. Verschraegen, Claire Stover, Daniel G. |
author_sort | Zhang, Yiqing |
collection | PubMed |
description | BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct clinical and genomic features of primary tumors. METHODS: Using three publicly-available datasets, we identified 453 patients diagnosed with primary TNBC with adequate follow-up to be characterized as ‘rapid relapse’ (rrTNBC; distant relapse or death ≤2 years of diagnosis), ‘late relapse’ (lrTNBC; > 2 years) or ‘no relapse’ (nrTNBC: > 5 years no relapse/death). We explored basic clinical and primary tumor multi-omic data, including whole transcriptome (n = 453), and whole genome copy number and mutation data for 171 cancer-related genes (n = 317). Association of rapid relapse with clinical and genomic features were assessed using Pearson chi-squared tests, t-tests, ANOVA, and Fisher exact tests. We evaluated logistic regression models of clinical features with subtype versus two models that integrated significant genomic features. RESULTS: Relative to nrTNBC, both rrTNBC and lrTNBC had significantly lower immune signatures and immune signatures were highly correlated to anti-tumor CD8 T-cell, M1 macrophage, and gamma-delta T-cell CIBERSORT inferred immune subsets. Intriguingly, lrTNBCs were enriched for luminal signatures. There was no difference in tumor mutation burden or percent genome altered across groups. Logistic regression mModels that incorporate genomic features significantly outperformed standard clinical/subtype models in training (n = 63 patients), testing (n = 63) and independent validation (n = 34) cohorts, although performance of all models were overall modest. CONCLUSIONS: We identify clinical and genomic features associated with rapid relapse TNBC for further study of this aggressive TNBC subset. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08320-7. |
format | Online Article Text |
id | pubmed-8130400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81304002021-05-19 Genomic features of rapid versus late relapse in triple negative breast cancer Zhang, Yiqing Asad, Sarah Weber, Zachary Tallman, David Nock, William Wyse, Meghan Bey, Jerome F. Dean, Kristin L. Adams, Elizabeth J. Stockard, Sinclair Singh, Jasneet Winer, Eric P. Lin, Nancy U. Jiang, Yi-Zhou Ma, Ding Wang, Peng Shi, Leming Huang, Wei Shao, Zhi-Ming Cherian, Mathew Lustberg, Maryam B. Ramaswamy, Bhuvaneswari Sardesai, Sagar VanDeusen, Jeffrey Williams, Nicole Wesolowski, Robert Obeng-Gyasi, Samilia Sizemore, Gina M. Sizemore, Steven T. Verschraegen, Claire Stover, Daniel G. BMC Cancer Research BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct clinical and genomic features of primary tumors. METHODS: Using three publicly-available datasets, we identified 453 patients diagnosed with primary TNBC with adequate follow-up to be characterized as ‘rapid relapse’ (rrTNBC; distant relapse or death ≤2 years of diagnosis), ‘late relapse’ (lrTNBC; > 2 years) or ‘no relapse’ (nrTNBC: > 5 years no relapse/death). We explored basic clinical and primary tumor multi-omic data, including whole transcriptome (n = 453), and whole genome copy number and mutation data for 171 cancer-related genes (n = 317). Association of rapid relapse with clinical and genomic features were assessed using Pearson chi-squared tests, t-tests, ANOVA, and Fisher exact tests. We evaluated logistic regression models of clinical features with subtype versus two models that integrated significant genomic features. RESULTS: Relative to nrTNBC, both rrTNBC and lrTNBC had significantly lower immune signatures and immune signatures were highly correlated to anti-tumor CD8 T-cell, M1 macrophage, and gamma-delta T-cell CIBERSORT inferred immune subsets. Intriguingly, lrTNBCs were enriched for luminal signatures. There was no difference in tumor mutation burden or percent genome altered across groups. Logistic regression mModels that incorporate genomic features significantly outperformed standard clinical/subtype models in training (n = 63 patients), testing (n = 63) and independent validation (n = 34) cohorts, although performance of all models were overall modest. CONCLUSIONS: We identify clinical and genomic features associated with rapid relapse TNBC for further study of this aggressive TNBC subset. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08320-7. BioMed Central 2021-05-18 /pmc/articles/PMC8130400/ /pubmed/34006255 http://dx.doi.org/10.1186/s12885-021-08320-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhang, Yiqing Asad, Sarah Weber, Zachary Tallman, David Nock, William Wyse, Meghan Bey, Jerome F. Dean, Kristin L. Adams, Elizabeth J. Stockard, Sinclair Singh, Jasneet Winer, Eric P. Lin, Nancy U. Jiang, Yi-Zhou Ma, Ding Wang, Peng Shi, Leming Huang, Wei Shao, Zhi-Ming Cherian, Mathew Lustberg, Maryam B. Ramaswamy, Bhuvaneswari Sardesai, Sagar VanDeusen, Jeffrey Williams, Nicole Wesolowski, Robert Obeng-Gyasi, Samilia Sizemore, Gina M. Sizemore, Steven T. Verschraegen, Claire Stover, Daniel G. Genomic features of rapid versus late relapse in triple negative breast cancer |
title | Genomic features of rapid versus late relapse in triple negative breast cancer |
title_full | Genomic features of rapid versus late relapse in triple negative breast cancer |
title_fullStr | Genomic features of rapid versus late relapse in triple negative breast cancer |
title_full_unstemmed | Genomic features of rapid versus late relapse in triple negative breast cancer |
title_short | Genomic features of rapid versus late relapse in triple negative breast cancer |
title_sort | genomic features of rapid versus late relapse in triple negative breast cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130400/ https://www.ncbi.nlm.nih.gov/pubmed/34006255 http://dx.doi.org/10.1186/s12885-021-08320-7 |
work_keys_str_mv | AT zhangyiqing genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT asadsarah genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT weberzachary genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT tallmandavid genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT nockwilliam genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT wysemeghan genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT beyjeromef genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT deankristinl genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT adamselizabethj genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT stockardsinclair genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT singhjasneet genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT winerericp genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT linnancyu genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT jiangyizhou genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT mading genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT wangpeng genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT shileming genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT huangwei genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT shaozhiming genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT cherianmathew genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT lustbergmaryamb genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT ramaswamybhuvaneswari genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT sardesaisagar genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT vandeusenjeffrey genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT williamsnicole genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT wesolowskirobert genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT obenggyasisamilia genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT sizemoreginam genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT sizemorestevent genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT verschraegenclaire genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer AT stoverdanielg genomicfeaturesofrapidversuslaterelapseintriplenegativebreastcancer |